CANY
ACAD icon

Caxton Associates (New York)’s Acadia Pharmaceuticals ACAD Stock Holding History

Caxton Associates (New York)’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,972
Closed -$289K – 292
2020
Q2 		$289K Buy
+5,972
New +$287K 0.03% 271

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Caxton Associates (New York)'s ACAD Position: Q3 2020 in Review

Caxton Associates (New York) sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 5,972 shares — an estimated $289K sold.

Caxton Associates (New York) first reported a position in ACAD in Q2 2020 and held it in 1 quarter. The position peaked at $289K in Q2 2020. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

  • Caxton Associates (New York) reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 5,972 Acadia Pharmaceuticals shares in Q3 2020, an estimated $289K.
  • Caxton Associates (New York) first reported a position in Acadia Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Caxton Associates (New York)'s Acadia Pharmaceuticals position peaked at $289K in Q2 2020.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Caxton Associates (New York)'s 13F filing for Q3 2020, filed 16 Nov 2020.